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Antitubercular activityAbstract The synthesis of some new 3,4-disubstituted thiazolylideneisonicotinohydrazide deriva-
tives 3a–k, 2-substituted thiazolidinylisonicotinamide derivatives 4a–d and pyrrolylisonicotinamide
derivatives 5, 6 and 7 is described. The resulted compounds are evaluated for their in vitro antitu-
bercular activity. The minimum inhibitory concentration (MIC) of compound 3g showed compara-
ble in vitro activity to isoniazid against Mycobacterium tuberculosis H37Ra 7131 strain in
concentration 9.77 lg/mL.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.1. Introduction
Tuberculosis (TB) is a common and often deadly infectious
disease caused by various strains of mycobacterium, mainly
Mycobacterium tuberculosis. Members of M. tuberculosis com-
plex areM. tuberculosis,M. africanum,M. bovis and the Bacil-
lus Calmette-Gue´rin strain,M. microti,M. canettii,M. caprae,
M. pinnipedii, and M. mungi. The species (M. avium complex,
M. gordonae, M. kansasii, M. simiae, M. chelonae, M. fortui-
tum, etc.) other than M. tuberculosis complex does not cause
tuberculosis in humans, TB usually attacks the lungs but can
also affect other parts of the body. It was considered to be a
disease of poverty for many years due to its rare occurrence
in developed countries.1 However, recently more people in
the developed world are contracting TB because their immunesystems are compromised by immunosuppressive drugs, sub-
stances abuse, or AIDS.2–5 Several decades ago, effective
anti-TB drugs were launched and one could hardly ﬁnd a TB
case demonstrated at medical universities. But the return of
TB was declared by the World Health Organization (WHO)
as a global emergency compared to a hypothetic third world
war with 9 million TB cases and two million deaths reported
each year; about one third of the world’s population is already
infected with M. tuberculosis.6 Moreover, recent advances in
diagnostics, drugs, and vaccines and enhanced implementation
of existing interventions have increased the prospects for
improved clinical care and global tuberculosis control.7
According to the 13th Annual Tuberculosis Report of the
WHO published on the world TB day on March 24, 2009, there
were 9.27 million new cases of TB estimated worldwide.4,8 The
terms associated with drug resistance in tuberculosis are very
important. The stages of tuberculosis in terms of developing
resistance are as follows: drug-sensitive tuberculosis, mono-
drug resistant tuberculosis, poly-drug resistant tuberculosis,
multi-drug resistant (MDR) tuberculosis, extensively drug
resistant (XDR) tuberculosis, and extremely drug resistant
(XXDR) tuberculosis. MDR-TB is deﬁned as resistance to
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46 M.A. Elhakeem et al.isoniazid and rifampicin, with or without resistance to other
ﬁrst-line anti-TB drugs. XDR-TB is deﬁned as resistance to at
least isoniazid and rifampicin from the ﬁrst-line anti-tuberculosis
drugs (the deﬁnition of MDR-TB) in addition to resistance to
any ﬂuoroquinolone, and to at least one of the three injectable
second-line anti-tuberculosis drugs (kanamycin, capreomycin
and amikacin). Multidrug Resistant Tuberculosis (MDR-TB)
proved resistant to at least rifampicin and isoniazid, the two
most frequently used anti-TB agents.5,9,10 Current treatment
programmes to combat TB are under threat due to the emer-
gence of multi-drug and extensively-drug resistant TB. As part
of our efforts towards the discovery of new anti-tubercular
leads, a number of potent tetrahydropyrazolo[1,5-a]pyrimi-
dine-3-carboxamide(THPP) and N-benzyl-60,70-dihydrospiro
[piperidine-4,40-thieno[3,2-c]pyran](Spiro) analogues were
recently identiﬁed against M. tuberculosis and Mycobacterium
bovis BCG through a high-throughput whole-cell screening
campaign.11
TB treatment strategy is tedious, long and has several side
effects. The currently applied classical drugs used to treat TB
include broad and narrow spectrum agents and different com-
binations targeting different types of TB. Such drugs are tradi-
tionally divided into two lines. First line drugs include
fundamental chemotherapeutics of choice, like isoniazid and
streptomycin. They are highly effective, but very susceptible
to resistant strains and must be administered for 6–9 months.
When these treatments fail, second line TB drugs are used. Sec-
ond line tuberculostatics are the most commonly used. How-
ever, these drugs have far lower efﬁcacy and require even
longer administration periods up to 18–24.12
Isoniazid (Fig. 1) is one of the active and successful agents
used to treat TB. It was considered as a starting point in the
search for new active derivatives and analogues such as hydra-
zones which have been reported as active anti-TB drugs
(Fig. 2).13–16
Nevertheless, the isoniazid therapy has two major draw-
backs. The ﬁrst one is its hepatotoxic effects. Isoniazid is
metabolized in the liver mainly by acetylation and dehydrazin-
ation. The N-acetylhydrazine metabolite is believed to be
responsible for the hepatotoxic effects. The second is its deac-
tivation by the action of N-arylaminoacetyltransferases
(NATs). These enzymes are found in both mycobacteria as
well as mammalian hosts, they deactivate isoniazid by acetyla-
tion reaction at N2 (terminal amino group) which is a step in
the metabolism of isonicotinic acid hydrazide (INH). The liter-
ature survey demonstrated the synthesis of isoniazid deriva-
tives such as hydrazones and Schiff’s bases, where N2 is
blocked towards acetylation by NATs.17 These derivatives
are more effective and less hepatotoxic than isoniazid.18
On the other hand, several heterocyclic compounds were
explored in the search for a reliable starting platform for
anti-TB drug development such as pyrrole derivatives. The
recently synthesized pyrrole LL-3858 (Sudoterb) (Fig. 3)N
O NHNH2
1 2
Figure 1 Isoniazid.showed higher bactericidal activity compared to isoniazid.
Sudoterb is active againstM. tuberculosis strains that are resis-
tant to available anti-TB drugs.19,20
Moreover, some drugs comprising a variety of ring systems
exhibited bactericidal activity such as thiazolidine derivatives
(Fig. 4).21,22
Guided by these ﬁndings, our rationale is to prepare new
potent and safe isoniazid derivatives. Our strategy to con-
struct new agents of isoniazid is based on the incorporation
of various heterocyclic rings that possess anti-TB activity
such as pyrrole and thiazolidine derivatives in the core struc-
ture of isoniazid with the aim of increasing their activity
through blocking position NH2 of the hydrazide group of
isoniazid.
2. Materials and methods
2.1. Chemistry
Melting points were determined on Grifﬁn apparatus and the
values given are uncorrected. IR spectra were determined on
Shimadzu IR 435 spectrophotometer (KBr, cm1). 1H NMR
Anti-mycobacterial evaluation 47spectra were recorded on Varian Gemini 200 and/or 300 MHz
spectrophotometer, 75 MHz for 13C using TMS as internal
standard. Chemical shift values are recorded in ppm on d scale,
at the Micro analytical centre, Cairo University, Egypt. Mass
spectra were recorded on a Hewlett Packard 5988 spectrome-
ter, at the Micro analytical centre, Cairo University, Egypt.
Elemental analyses were carried out at the Micro analytical
centre, Cairo University, Egypt. Progress of the reactions
was monitored using TLC sheets pre-coated with UV ﬂuores-
cent silica gel Merck 60F 254 using acetone/benzene (1:9) and
were visualized using UV lamp. LogP was calculated using
Chem. Draw Ultra 9.0 program. All chemicals were obtained
from Aldrich, Fluka, or Merck chemicals.
2.1.1. N0-[3,4-Disubstitutedthiazol-2(3H)-ylidene]
isonicotinohydrazide (3a–k)
A mixture of the appropriate 2a–e (0.01 mol) and the selected
phenacyl bromide (0.01 mol) in 99% ethanol and chloroform
mixture (1:1) (20 mL) was heated under reﬂux for 3 h. The
reaction mixture was concentrated under vacuum to half its
volume, cooled and the formed precipitate was ﬁltered, dried
and recrystallized from benzene/petroleum ether.
2.1.1.1. N0-(4-(4-Bromophenyl)-3-ethylthiazol-2(3H)-ylidene)
isonicotinohydrazide (3a). Yield 62%; mp 186–187 C (ben-
zene/petroleum ether); (MS (EI) m/z (% rel. Int.): 402 (M+,
48.10%), 404 (M+2, 54.30%); IR (KBr) cm1: 3444 (NH),
2978, 2947(CH aliphatic), 1666(C‚O); 1H NMR (DMSO-
d6) d (ppm) (300 MHz): 0.94 (t, 3H, J= 7.2 Hz, ACH2ACH3),
3.59 (q, 2H, J= 7.2 Hz, ACH2ACH3), 6.80 (s, 1H, ‚CH of
thiazole), 7.25–7.77 (m, 2H, Ar-H), 7.87 (d, 2H, J= 6 Hz, pyr-
idine H-3, H-5), 8.08–8.91 (m, 2H, Ar-H), 8.93 (d, 2H,
J= 6 Hz, pyridine H-2, H-6), 11.70 (s, 1H, NH, D2O
exchangeable); Anal. Calcd for C17H15BrN4OS, Mwt.
(403.3): C, 50.63; H, 3.75; N, 13.89; Found; C, 50.54; H,
3.65; N, 13.80.
2.1.1.2. N0-(3-Allyl-4-(4-bromophenyl)thiazol-2(3H)-yli-
dene)isonicotinohydrazide (3b). Yield 57%; mp 156–157 C
(benzene/petroleum ether); IR (KBr) cm1: 3394 (NH), 2997,
2931(CH aliphatic), 1647(C‚O); 1H NMR (DMSO-d6) d
(ppm) (300 MHz): 4.38 (d, 2H, N-CH2), 4.92–5.15 (m, 2H,
CH2‚CH of allyl), 5.78–5.80 (m, 1H, CH‚CH2 of allyl),
6.38 (s, 1H, ‚CH of thiazole), 7.40–7.43 (m, 2H, Ar-H),
7.67–7.70 (m, 2H, Ar-H), 7.75 (d, 2H, J= 6 Hz, pyridine
H-3, H-5), 8.72 (d, 2H, J= 6 Hz, pyridine H-2, H-6), 11.02
(s, 1H, NH, D2O exchangeable); Anal. Calcd for C18H15BrN4
OS, Mwt. (415.31): C, 52.06; H, 3.64; N, 13.49; Found; C,
52.11; H, 3.55; N, 13.71.
2.1.1.3. N0-(4-(4-Bromophenyl)-3-phenylthiazol-2(3H)-yli-
dene)isonicotinohydrazide (3c). Yield 59%; mp 262–267 C;
(benzene/petroleum ether); MS (EI) m/z (%.): 450 (M+,
94.68%), 452 (M+2, 98.01%); IR (KBr) cm1: 3441 (NH),
1693(C‚O); 1H NMR (DMSO-d6) d (ppm) (300 MHz): 6.62
(s, 1H, ‚CH thiazole), 7.13–7.15 (m, 5H, Ar-H), 7.26–7.46
(m, 4H, Ar-H), 7.72 (d, 2H, J= 6 Hz, pyridine H-3, H-5),
8.71 (d, 2H, J= 6 Hz, pyridine H-2, H-6), 10.91 (s, 1H, NH,
D2O exchangeable);
13C NMR (75 MHz, DMSO-d6 TMS):
163.54(C‚O), 147.54(C‚N), (140.97, 139.16)(C2,6 pyridine),
135.05(C-Br), 134.12(C), 133.94(C), 133.73(C), 131.38(C),130.26(C), 130.13(C), 128.83(C), 128.25(C), 127.91(C),
127.24(C), 126.10(C), 125.53(C), (123.84, 122.80)(C3,5
pyridine), 120.86(C), 101.91 (‚CH thiazole); Anal. Calcd for
C21H15BrN4OS, Mwt. (451.34): C, 55.88; H, 3.35; N, 12.41;
Found; C, 55.49; H, 3.31; N,12.09.
2.1.1.4. N0-(4-(4-Bromophenyl)-3-p-tolylthiazol-2(3H)-yli-
dene)isonicotinohydrazide (3d). Yield 63%; mp 125–127 C
(benzene/petroleum ether); MS (EI) m/z (%.): 464 (M+,
57.88%), 466 (M+2, 61.50%) IR (KBr) cm1: 3420 (NH),
2920 (CH aliphatic), 1689 (C‚O); 1H NMR (DMSO-d6) d
(ppm) (300 MHz): 2.28 (s, 3H, CH3), 6.70 (s, 1H, ‚CH thia-
zole), 7.14–7.23 (m, 4H, Ar-H), 7.46–7.50 (m, 4H, Ar-H),
7.85 (d, 2H, J= 6 Hz, pyridine H-3, H-5), 8.79 (d, 2H,
J= 6 Hz, pyridine H-2, H-6), 11.20 (s, 1H, NH, D2O
exchangeable); Anal. Calcd for C22H17BrN4OS, Mwt.
(465.37): C, 56.78; H, 3.68; N, 12.04; Found; C, 56.92; H,
3.65; N, 12.43.
2.1.1.5. N0-(4-(4-Chlorophenyl)-3-ethylthiazol-2(3H)-ylidene)
isonicotinohydrazide (3e). Yield 58%; mp 210–211 C (ben-
zene/petroleum ether); MS (EI) m/z (%): 358 (M+, 96.69%),
360 (M+2, 37.28%); IR (KBr) cm1: 3414 (NH), 2978, 2947
(CH aliphatic), 1665 (C‚O); 1H NMR (DMSO-d6) d (ppm)
(200 MHz): 0.96 (t, 3H, J= 7.2 Hz, CH2A 2H, Ar-H), 6.74
(s, 1H, ‚CH thiazole), 7.63 (d, 2H, J= 6 Hz, pyridine H-3,
H-5), 8.89 (d, 2H, J= 6 Hz, pyridine H-2, H-6), 8.97–9.06
(m, 2H, Ar-H), 11.77 (s, 1H, NH, D2O exchangeable); Anal.
Calcd for C17H15ClN4OS, Mwt. (358.85): C, 56.90; H, 4.21;
N, 15.61; Found; C, 56.55; H, 4.54; N, 15.23.
2.1.1.6. N0-(3-Allyl-4-(4-chlorophenyl)thiazol-2(3H)-ylidene)
isonicotinohydrazide (3f). Yield 52%; mp 200–203 C (ben-
zene/petroleum ether); MS (EI) m/z (%): 369 (M1, 6.47%),
370 (M+, 32.19%), 372 (M+2, 12.67.50%); IR (KBr) cm1:
3417 (NH), 2924 (CH aliphatic), 1685 (C‚O); 1H NMR
(DMSO-d6) d (ppm) (300 MHz): 4.35 (d, 2H, N-CH2), 4.85–
5.21 (m, 2H, CH‚CH2), 5.40–5.85 (m, 1H, CH‚CH2), 6.68
(s, 1H, ‚CH thiazole), 7.18–7.57 (m, 2H, Ar-H), 7.82 (d,
2H, J= 6 Hz, pyridine H-3, H-5), 8.88 (d, 2H, J= 6 Hz, pyr-
idine H-2, H-6), 8.94–8.96 (m, 2H, Ar-H), 11.72 (s, 1H, NH,
D2O exchangeable);
13C NMR) (75 MHz, DMSO-d6 TMS):
202.60(C‚O), 151.26(C‚N), (147.63, 146.27)(C2,6 pyridine),
140.80(C), 137.39(C), 134.07(C), 132.85(C-Cl), 131.14(C),
128.89(C), (128.46, 128.15)(C3,5 pyridine), 126.03(C)
122.84(C), 121.38(C), 116.18(C), 91.22 (‚CH thiazole),
42.73(CH2); Anal. Calcd for C18H15ClN4OS, Mwt. (370.86):
C, 58.30; H, 4.08; N, 15.11; Found; C, 58.61; H, 4.06; N, 15.09.
2.1.1.7. N0-(4-(4-Chlorophenyl)-3-phenylthiazol-2(3H)-yli-
dene)isonicotinohydrazide (3g). Yield 51%; mp 243–
245 C(benzene/petroleum ether); MS (EI) m/z (%): 406
(M+, 100%), 408 (M+2, 35.89%); IR (KBr) cm1: 3421
(NH), 1670 (C‚O); 1H NMR (DMSO-d6) d (ppm)
(300 MHz): 6.84 (s, 1H, ‚CH of thiazole), 7.21–7.47 (m,
2H, Ar-H), 7.61 (d, 2H, J= 6 Hz, pyridine H-3, H-5), 8.05
(d, 2H, J= 6 Hz, pyridine H-2, H-6), 8.85–8.95 (m, 2H, Ar-
H), 11.50 (s, 1H, NH, D2O exchangeable);
13C NMR
(75 MHz, DMSO-d6.TMS): 168.77(C‚O), 160.57,
150.13(C‚N), (140.77, 138.25)(C2,6 pyridine), 137.16(C),
131.22(C-Cl), 130.11(C), 129.74(C), 128.97(C),
(128.13,128.57)(C3,5 pyridine), 127.97(C) 121.84(C),
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120.62(C), 99.92 (‚CH thiazole). Anal. Calcd for C21H15-
ClN4OS, Mwt. (406.89): C, 61.99; H, 3.72; N, 13.77; Found;
C, 61.71; H, 3.76; N, 13.65.
2.1.1.8. N0-(4-(4-Chlorophenyl)-3-p-tolylthiazol-2(3H)-yli-
dene)isonicotinohydrazide (3h). Yield 51%; mp 225–227 C
(benzene/petroleum ether); MS (EI) m/z (%): 420 (M+,
50.50%), 422 (M+2, 19.60%), IR (KBr) cm1: 3421 (NH),
2947, 2920 (CH aliphatic), 1697 (C‚O); 1H NMR (DMSO-
d6) d (ppm) (300 MHz): 2.28 (s, 3H, CH3), 6.60 (s, 1H,‚CH thi-
azole), 7.12–7.18 (m, 4H, Ar-H), 7.20–7.22 (m, 2H, Ar-H), 7.32–
7.35 (m, 2H, Ar-H), 7.72 (d, 2H, J= 6 Hz, pyridine H-3, H-5),
8.72 (d, 2H, J= 6 Hz, pyridine H-2, H-6), 10.96 (s, 1H, NH,
D2O exchangeable);
13C NMR (75 MHz, DMSO-d6.TMS):
186.88 (C‚O), 179.91 (C‚N), 158.66, (148.35, 146.97)
(C2,6 pyridine), 142.21(C), 138.94(C), 138.05(C), 133.67(C),
132.24(C), 131.84(C-Cl), 131.25(C), 130.83(C), 129.71(C),
129.33(C), 128.49(C), 127.77(C), 125.61(C), (122.91,
120.77)(C3,5 pyridine), 92.73(‚CH thiazole), 20.54(CH3);
Anal. Calcd for C22H17ClN4OS, Mwt. (420.91): C, 62.78; H,
4.07; N, 13.31; Found; C, 62.71; H, 4.11; N, 13.54.
2.1.1.9. N0-(3-Ethyl-4-(3-nitrophenyl)thiazol-2(3H)-yli-
dene)isonicotinohydrazide (3i). Yield 51%; mp 216–217 C;
(benzene/petroleum ether); MS (EI) m/z (%): 369 (M+,
100%) IR (KBr) cm1: 3421 (NH), 2978, 2908 (CH aliphatic),
1705 (C‚O), 1530 (NO2);
1H NMR (DMSO-d6) d (ppm)
(300 MHz): 1.15 (t, 3H, J= 7.2 Hz, ACH2ACH3), 3.80 (q,
2H, J= 7.2 Hz, ACH2ACH3), 6.49 (s, 1H,‚CH of thiazole),
7.76–7.84, (m, 3H, Ar-H), 7.96 (d, 2H, J= 6 Hz, pyridine H-3,
H-5), 8.27–8.36 (m, 1H, Ar-H), 8.73 (d, 2H, J= 6 Hz, pyridine
H-2, H-6), 11.03 (s, 1H, NH, D2O exchangeable);
13C NMR,
(75 MHz, DMSO-d6.TMS): 168.10(C‚O), 161.10(C‚N),
(150.40, 147.86)(C2,6 pyridine), 140.92(C) 137.92(C),
134.98(C), 131.82(C), 130.50(C), 123.95(C), 123.21(C), 121.20,
(120.70,120.60)(C3,5 pyridine), 8, 99.72(‚C thiazole),
40.52(CH2), 12.72(CH2); Anal. Calcd for C17H15N5O3S, Mwt.
(369.04): C, 55.27; H, 4.09; N, 18.96; Found; C, 55.08; H,
4.31; N, 18.76.
2.1.1.10. N0-(3-Allyl-4-(3-nitrophenyl)thiazol-2(3H)-yli-
dene)isonicotinohydrazide (3j). Yield 60%; mp 230–231 C
(benzene/petroleum ether); MS (EI) m/z (%): 381 (M+,
16.01%); IR (KBr) cm1: 3421, 3244 (NH), 2981 (CH ali-
phatic), 1639(C‚O), 1531 (NO2);
1H NMR (DMSO-d6) d
(ppm) (300 MHz): 4.07 (d, 2H, N-CH2), 4.93–5.24 (m, 2H,
‚CH2), 5.75–5.96 (m, 1H, CH‚), 6.65 (s, 1H, ‚CH thia-
zole), 7.70–7.89 (m, 3H, Ar-H), 7.94 (d, 2H, j= 6 Hz, pyridine
H-3, H-5), 7.95–8.11 (m, 1H, Ar-H), 8.80 (d, 2H, J= 6 Hz,
pyridine H-2, H-6), 12.02 (s, 1H, NH, D2O exchangeable);
Anal. Calcd for C18H15N5O3S, Mwt. (381.41): C, 56.68; H,
3.96; N, 18.36; Found; C, 56.43; H, 3.95; N, 18.44.
2.1.1.11. N0-(4-(3-Nitrophenyl)-3-p-tolylthiazol-2(3H)-yli-
dene)isonicotinohydrazide (3k). Yield 60%; mp 100–101 C
(benzene/petroleum ether); MS (EI) m/z (%): 431 (M+,
23.65), 432 (M+1, 7.38%), 433 (M+2, 3.14%);IR (KBr)
cm1: 3421 (NH), 2920 (CH aliphatic), 1666 (C‚O), 1527
(NO2);
1H NMR (DMSO-d6) d (ppm) (300 MHz): 2.28 (s,
3H, CH3), 6.83 (s, 1H, ‚CH thiazole), 7.19–7.59 (m, 3H,
Ar-H), 7.72 (d, 2H, J= 6 Hz, pyridine H-3, H-5), 8.05–8.12(m, 1H, Ar-H), 8.73 (d, 2H, J= 6 Hz, pyridine H-2, H-6),
11.02 (s, 1H, NH, D2O exchangeable); Anal. Calcd for
C22H17N5O3S, Mwt. (431.47): C, 61.24; H, 3.97; N, 16.23;
Found; C, 61.31; H, 3.88; N, 16.09.
2.1.2. N-[2-(Substituted imino)-4,5-dioxo[1,3]thiazolidin-3-
yl]isonicotinamide (4a–d)
A mixture of the appropriate 2a, b, d and e (0.01 mol) anhy-
drous potassium carbonate (2.8 g, 0.02 mol) and oxalyl chlo-
ride (1.9 g, 0.015 mol) in dry benzene (20 mL) was heated
under reﬂux with stirring for 7 h. The formed precipitate was
ﬁltered while hot, washed twice with water (10 mL), dried
and recrystallized from chloroform/petroleum ether.
2.1.2.1. N-(2-(Ethylimino)-4,5-dioxothiazolidin-3-yl)isonicoti-
namide (4a). Yield 60%; mp 150–152 C (chloroform/
petroleum ether); MS (EI) m/z (%): 278 (M+, 5.20%) IR
(KBr) cm1: 3402 (NH), 2931 (CH aliphatic), 1789, 1765,
1708 (3C‚O); 1H NMR (DMSO-d6) d (ppm) (300 MHz):
1.05 (t, 3H, J= 7.2 Hz, ACH2ACH3), 3.48 (q, 2H,
J= 7.2 Hz, ACH2ACH3), 8.08 (d, 2H, J= 6 Hz, pyridine
H-3, H-5), 8.91 (d, 2H, J= 6 Hz, pyridine H-2, H-6), 12.30
(s, 1H, NH, D2O exchangeable);
13C NMR (75 MHz,
DMSO-d6, TMS): 178.91(C‚O), 165.15(C‚O),
163.67(C‚O), 153.94(C‚N),(149.29, 147.45)(C2,6 pyridine),
145.23(C), (124.22, 122.21)(C3,5 pyridine), 37.49(CH2),
14.33(CH3); Anal. Calcd for C11H10N4O3S, Mwt. (278.29):
C, 47.48; H, 3.62; N, 20.13; Found; C, 47.59; H, 3.41; N, 20.44.
2.1.2.2. N-(2-(Allylimino)-4,5-dioxothiazolidin-3-yl)isonicoti-
namide (4b). Yield 60%; mp 203–205 C; (chloroform/
petroleum ether); MS (EI) m/z (%): 293 (M+3H, 0.92%);
IR (KBr) cm1: 3263 (NH), 2924 (CH aliphatic), 1720, 1705,
1678 (3C‚O); 1H NMR (DMSO-d6) d (ppm) (300 MHz):
4.10 (d, 2H, N-CH2), 5.03–5.16 (m, 2H, ‚CH2), 5.78–5.89
(m, 1H, CH‚), 7.81 (d, 2H, J= 6 Hz, pyridine H-3, H-5),
8.77 (d, 2H, J= 6 Hz, pyridine H-2, H-6), 10.64 (s, 1H, NH,
D2O exchangeable);
13C NMR (75 MHz, DMSO-d6.TMS):
182.00(C‚O), 166.49(C‚O), 165.02(C‚O), (150.67,
150.24)(C2,6 pyridine), 139.98(C‚N), 138.54(C), 134.94(C),
(123.14, 122.07)(C2,5 pyridine), 115.67(C), 46.67(CH2); Anal.
Calcd for C12H10N4O3S, Mwt. (290.3): C, 49.65; H, 3.47; N,
19.30; Found; C, 49.66; H, 3.61; N, 19.05.
2.1.2.3. N-(4,5-Dioxo-2-(phenylimino)thiazolidin-3-yl)isonico-
tinamide (4c). Yield 60%; mp 160–162 C; (chloroform/petro-
leum ether); MS (EI) m/z (%): 341 (M+H, 41.50%); IR (KBr)
cm1: 3421 (NH), 2912 (CH aliphatic), 1789, 1724, 1693
(3C‚O); 1H NMR (DMSO-d6) d (ppm) (300 MHz): 2.33 (s,
3H, CH3), 7.03–7.46 (m, 4H, Ar-H), 7.88 (d, 2H, J= 6 Hz,
pyridine H-3, H-5), 8.85 (d, 2H, J= 6 Hz, pyridine H-2,
H-6), 12.25 (s, 1H, NH, D2O exchangeable);
13C NMR
(75 MHz, DMSO-d6,TMS): 184.00(C‚O), 174.10(C‚O),
165.62(C‚O), 153.80(C‚N), (150.00, 148.85)(C2,6 pyridine),
139.80(C), 138.97(C), 131.85(C), 128.98(C), 128.22, 125.19,
123.52,(121.85, 121.01)(C3,5 pyridine), 20.67(CH3) Anal. Calcd
for C16H12N4O3S, Mwt. (340.36): C, 56.46; H, 3.55; N, 16.46;
Found; C, 56.81; H, 3.90; N, 16.54.
2.1.2.4. N-(4,5-Dioxo-2-(p-tolylimino)thiazolidin-3-yl)isonico-
tinamide (4d). Yield 63%; mp 190–192 C; (chloroform/petro-
Table 1 MIC of tested compounds 3a–c, 3f–k, 4a–d, 5, 6 and
7.
Compound MIC (mg/mL) LogP
3a 39 4.27
3b 19.5 4.63
3c 78 5.76
3f 39 4.36
3g 9.77 5.49
3h 19.5 5.49
3i 78 2.76
3j 78 2.97
3k 39 3.60
4a 19.5 0.76
4b 19.5 0.42
4c 19.5 2.57
4d 78 2.57
5 78 1.05
6 19.5 0.73
7 39 0.74
Isoniazid 1.22 0.60
Anti-mycobacterial evaluation 49leum ether); IR (KBr) cm1: 3417 (NH), 2912 (CH aliphatic),
1793, 1716, 1697 (3C‚O); 1H NMR (DMSO-d6) d (ppm)
(300 MHz): 2.35 (s, 3H, CH3), 6.86–7.39 (m, 4H, Ar-H), 7.98
(d, 2H, J= 6 Hz, pyridine H-3, H-5), 8.90 (d, 2H, J= 6 Hz,
pyridine H-2, H-6), 12.40 (s, 1H, NH, D2O exchangeable);
13C NMR (75 MHz, DMSO-d6, TMS): 179.21(C‚O)),
163.78(C‚O), 153.93(C‚O), 152.44(C‚N), (149.91,
148.97)(C2,6 pyridine), 139.76(C) 139.39(C), 138.42(C),
129.72(C), 129.43(C), 127.95(C), 123.47(C), (121.96,
120.77),(C3,5 pyridine) 20.76(CH3); Anal. Calcd for C16H12N4-
O3S Mwt. (340.36): C, 56.46; H, 3.55; N, 16.46; Found; C,
56.82; H, 3.81; N, 16.79.
2.1.3. General procedure of compounds 5, 6 and 7
A mixture of 1 (1.37, 0.01 mol), 2-acetyl-c-butyrolactone or
the selected anhydride (0.01 mol) and glacial acetic acid
(10 mL) with few drops of acetic anhydride was heated under
reﬂux for 13 h. The reaction mixture was cooled and poured
onto ice-cold water (20 mL). The formed precipitate was
ﬁltered, washed twice with water (20 mL), dried and recrystal-
lized from methanol.
2.1.3.1. N-(3-Acetyl-2-oxopyrrolidin-1-yl)isonicotinamide (5).
Yield 43%; mp 150–152 C; (methanol), MS (EI) m/z (%):
247 (M+, 0.09%); IR (KBr) cm1: 3429 (NH), 2924, 2854RCNS, ethanol, reflux 4h
C
H
NO
N S
N
R
OO
C
H
NO
NH2
N
C
H
NO
N
H
C
S
N
R
N
N
No. R
4a C2H5
4b -CH2-CH=CH2
4c m- CH3-C6H4
4d p- CH3-C6H4
2a-e
4a-d
i
ii
Reagents and conditions: i=
ii= (COCl)2, dry benzene, re
iii= substituted phenacylbrom
1
Scheme 1 Synthesis of target(CH aliphatic), 1735, 1705, 1658 (3C‚O); 1H NMR
(DMSO-d6) d (ppm) (300 MHz): 1.98 (s, 3H, CH3), 2.05–2.07.
H
H
N
N S
N
R
C
N
X
No. R
2a C2H5
2b -CH2-CH=CH2
2c -C6H5
2d m-CH3-C6H4
2e p-CH3-C6H4
No. R X
3a C2H5 p-Br
3b -CH2-CH=CH2 p-Br
3c -C6H5 p-Br
3d p-CH3-C6H4 p-Br
3e -C2H5 p-Cl
3f -CH2-CH=CH2 p-Cl
3g -C6H5 p-Cl
3h p- CH3-C6H4 p-Cl
3i -C2H5 m-NO2
3j -CH2-CH=CH2 m-NO2
3K p- CH3-C6H4 m-NO2
3a-k
iii
O
flux 3h.
ide, ethanol/methanol, reflux 7h.
compounds 3a–k and 4a–d.
C
H
NO
N
O
C
CH3
O
C
H
NO
NH2
C
H
NO
N
O
O
C
H
NO
N
O
O
N
N
N
N
1
5
6
7
i
ii
iii
i= 2-acetyl-3-butyrolactone, gl.acetic acid/acetic anhydride,reflux 13h.
ii= maleic anhydride, gl.acetic acid/acetic anhydride, reflux 13h.
iii= phenyl succinic anhydride, gl.acetic acid/acetic anhydride, reflux 13h.
Reagents and condition
Scheme 2 Synthesis of target compounds 5, 6 and 7.
50 M.A. Elhakeem et al.(m, 2H, CH2ACH), 2.49 (t, 1H, CH2ACH), 3.97 (t, 2H, CH2-
AN), 7.80 (d, 2H, J= 6 Hz, pyridine H-3, H-5), 8.78 (d, 2H,
J= 6 Hz, pyridine H-2, H-6), 11.90 (s, 1H, NH, D2O
exchangeable); Anal. Calcd for C12H13N3O3, Mwt. (247.25):
C, 58.29; H, 5.30; N, 16.99; Found; C, 58.33; H, 5.60; N, 16.92.
2.1.3.2. N-(2,5-Dioxo-2H-pyrrol-1(5H)-yl)isonicotinamide
(6). Yield 50%; mp 205–207 C; (methanol). IR (KBr)
cm1: 3429 (NH), 3097 (CH aromatic), 1730, 1689, 1651
(3C‚O); 1H NMR (DMSO-d6) d (ppm) (300 MHz): 6.63 (s,
2H, CH‚CH), 7.79 (d, 2H, J= 6 Hz, pyridine H-3, H-5),
8.79 (d, 2H, J= 6 Hz, pyridine H-2, H-6), 10.94 (s, 1H, NH,
D2O exchangeable); Anal. Calcd for C10H7N3O3, Mwt.
(217.18): C, 55.30; H, 3.25; N, 19.35; Found; C, 55.66; H,
3.15; N, 19.41.
2.1.3.3. N-(2,5-Dioxo-3-phenylpyrrolidin-1-yl)isonicotinamide
(7). Yield 59%; mp 230–231 C; (methanol). MS (EI) m/z
(%): 295 (M+, 4.93%) IR (KBr) cm1: 3429 (NH), 2974,
2858 (CH aliphatic), 1732, 1681, 1662 (3C‚O); 1H NMR
(DMSO-d6) d (ppm) (300 MHz): 2.87, 3.31 (2d, 2H, CH2),
3.48–3.51 (2d, 1H, CH-ph), 7.30–7.36 (m, 5H, Ar-H), 7.81
(d, 2H, J= 6 Hz, pyridine H-3, H-5), 8.80 (d, 2H, J= 6 Hz,
pyridine H-2, H-6), 11.60 (s, 1H, NH, D2O exchangeable);
13C NMR (75 MHz, DMSO-d6.TMS): 74.77(C‚O),
173.00(C‚O), 164.47(C‚O), (150.53, 150.38),(C2,6 pyridine),139.35(C), 128.86(C), 127.75(C), 127.64(C), 122.76(C),
121.38(C), (120.90, 120.83),(C3,5 pyridine), 120.77(C),
43.80(CH), 35.59(CH2); Anal. Calcd for C16H13N3O3, Mwt.
(295.29): C, 65.08; H, 4.44; N, 14.23; Found; C, 65.06; H,
4.30; N, 14.01.
2.2. Antituberculous activity
The minimum inhibitory concentration (MIC) was recorded as
the highest dilution of a compound inhibiting bacterial growth.
MIC of the selected compounds against M. tuberculosis
H37Ra 7131 strain was evaluated in liquid medium by the
broth dilution method according to the modiﬁed method of
Heifets.28,23
2.2.1. Preparation of stock solutions of the selected compounds
Stock solutions of the compounds were prepared by dissolving
104 mg of each compound in dimethylsulphoxide (1 mL). Fur-
ther dilutions were performed in Middlebrook broth 7H9
medium.
2.2.2. Preparation of inoculum
Inoculum was prepared by scrapping colonies of 21 days-old
culture of the bacilli from the surface of solid drug-free Middle
brook agar 7H10 medium. The bacterial mass was transferred
Anti-mycobacterial evaluation 51to a sterile 16 · 25 mm, screw capped tube containing glass
beads and 4 mL of Middle brook 7H9 medium. The mixture
was homogenized for 2 min. and allowed to stand undisturbed
for 30 min. Supernatant suspension was withdrawn and
adjusted to the turbidity equivalent to 0.5 McFarland standard
using Middle brook 7H9 medium.
2.2.3. Broth dilution
In sterile screw capped tubes, two fold serial dilutions of each
compound were prepared in Middle brook broth 7H9 medium
with a ﬁnal volume of 1 mL. Each tube was inoculated with
0.05 mL of prepared bacterial suspension. A positive growth
control was prepared by inoculating 0.05 mL of bacterial sus-
pension into a tube containing Middle brook 7H9 broth with
no drugs. A positive control for antimycobacterial activity
was included using a solution of isoniazid prepared at the same
concentration and inoculated the same way as the compounds
under test. Tubes were incubated for three weeks at 37 C in a
moisturized incubator and were examined for bacterial growth
after 21 days. Results were the mean of two independent exper-
iments and the data are represented in Table 1.3. Results and discussion
3.1. Chemistry
The thiosemicarbazide derivatives 2a–e which are considered
as the key intermediates in Schemes 1 and 2 were prepared
according to reported procedures.23–25 The synthesis of com-
pounds 3a–k was achieved through the efﬁcient synthetic route
outlined in Scheme 1. Cyclocondensation reaction of the thi-
osemicarbazides 2a–e with the appropriate phenacyl bromide
afforded the corresponding thiazolidine 3a–k.25,26 Cyclization
of 2a–e using oxallyl chloride yielded the thiazolidinedione
derivatives 4a–d6,26,27 (Scheme 1). Scheme 2 involves the syn-
thesis of the pyrrolyl derivatives 5, 6 and 7.27,28 Reaction of
isoniazid with either a number of acid anhydrides such as
maleic acid anhydride, phenyl succinic anhydride or 2-acetyl-
c-butyrolactone seemed to be a convenient route to fulﬁll this
aim. Structures of the synthesized compounds were established
on the basis of elemental analysis and spectral data (IR, 13C
NMR, 1H NMR and Mass spectra).
In general, IR spectra of compounds 3a,b,d–f,h–k showed the
appearance of absorption band at 2978–2920 cm1 indicating
aliphatic substituents whereas compounds 4a–d revealed the
presence of carbonyl groups of thiazolidinedione ring ranging
from 1793 to 1705 cm1. Furthermore, IR spectra of pyrrolidi-
nones 5, 6 and 7 demonstrated extra carbonyl band ranging
from 1730 to 1705 cm1. On the other hand, 1H NMR of
compounds 3a–k showed a singlet signal of the thiazole ring at
6.31–6.87 ppm.3.2. Antimycobacterial activity
3.2.1. Preliminary in vitro antitubercular screening
MIC of the selected compounds 3a–c, 3f–k, 4a–d, 5, 6 and 7
were subjected to antimycobacterial evaluation against M.
tuberculosis H37Ra 7131 strain in liquid medium by the broth
dilution method according to modiﬁed method of Heifets.28,234. Conclusion
The objective of the present study was to construct new agents
of isoniazid based on the incorporation of various heterocyclic
rings that possess anti-TB activity such as pyrrole and thiazol-
idine derivatives in the core structure of isoniazid with the aim
of increasing their activity.
Results showed that compound 3g, a thiazolidine derivative,
has comparable activity to that of isoniazid while compounds
3b, 3h, 4a, 4b, 4c, 3a and 3f exhibited moderate anti-TB activity.
In addition, compounds 3c, 3i, 3j and 4d demonstrated poor
anti-TB activity. On the other hand, the pyrrolyl derivative 6
was found to bemore active than compounds 5 and 7 yet it is less
active than the thiazolidine derivatives. LogP are calculated for
the tested compounds using Chem. Draw Ultra 9.0 program.
This revealed that compounds with high LogP value have low
MIC. This indicates that increasing the lipophilic moieties in
the structure leads to an increase in LogP values. Other tested
compounds showed lower activity with higher MIC ranging
from 19.5 to 78 lg/mL. The mechanism of action of newly syn-
thesized nicotinamide adenine dinucleotide compounds may
resemble that of isoniazid which is the peroxidative activation
of isoniazid by themycobacterial enzyme (KatG)M. tuberculosis
catalase–peroxidase enzyme that generates reactive species
forming adducts with (NAD+) the oxidized form of the NAD
coenzyme nicotinamide adenine dinucleotide and (NADP+)
NAD is also converted into nicotinamide adenine dinucleotide
phosphate (NADP); which are potent inhibitors of lipid and
nucleic acid biosynthetic enzymes.29
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